Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,184.40up ₹8.90 (0.76%)BSE ₹1,186.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.50.
29 Oct: open ₹1,175.50, high ₹1,187.80, low ₹1,170.50
52-week range of traded prices to 29 Oct 2026
₹835.50Low, 2 Apr 2026₹1,232.10High, 29 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,18,144 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.18
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 23.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.36
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,55,85055.6% delivered
Zydus Lifesciences disputes and clarifications
33 filed, newest first.
Apr 2025
Mar 2025
3 Mar · Legal
Jan 2025
25 Jan · Legal
21 Jan · Legal
Nov 2024
29 Nov · Legal
Sep 2024
29 Sep · Legal
May 2019
14 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned- "Pharma stocks bleed as US states file lawsuit against generic drug firms". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company was aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Nov 2018
May 2018
28 May · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Nov 2017
10 Nov · Legal
Exchange has sought clarification from the Company with respect to news item captioned Zydus Cadila, Intas under scanner for launching hypertension drug without permit. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Jan 2017
20 Jan · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to announcement dated January 19, 2017, regarding a press release dated January 19, 2017, titled "Zydus Cadila acquires Sentynl Therapeutics Inc., a US based specialty pharmaceutical company.On basis of above the Company is required to clarify following:1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Brief details of any governmental or regulatory approvals required for the acquisition;4. Indicative time period for completion of the acquisition;5. Nature of consideration - whether cash consideration or share swap and details of the same;6. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.18 Jan · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Cadila Set to buy US Firm for $171m .In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Dec 2016
Nov 2016
23 Nov · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Vietnam blacklists 39 Indian drug Cos for violation of standards. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Aug 2016
8 Aug · Legal
Exchange had sought clarification from Cadila Healthcare Limited with respect to an announcement submitted to the Exchange dated August 08, 2016, regarding a press release dated August 08, 2016 titled "Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India".On basis of above Company has clarified as follows-1. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";Company Reply - The acquisition does not fall within related party transactions and promoter/promoter group or group entities have no interest in the acquisition. Please also note that the acquisition is of brand and not an entity. 2. Cost of acquisition;Company Reply - As a corporate policy, we do not reveal the cost of acquisition from the confidentiality angle. However, we can mention that it is not a material transaction.3. Nature of consideration - whether cash consideration or share swap and details of the same; Company Reply - The consideration is on cash basis.4. Brief details of any governmental or regulatory approvals required for the acquisition; Company Reply - In our opinion, no approvals are required from any governmental or regulatory agencies for this acquisition of brand.8 Aug · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to an announcement submitted to the Exchange dated August 08, 2016, regarding a press release dated August 08, 2016 titled "Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India".On basis of above Company are required to clarify following -1. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";2. Cost of acquisition;3. Nature of consideration - whether cash consideration or share swap and details of the same;4. Brief details of any governmental or regulatory approvals required for the acquisition; The response of the Company is awaited.
Jul 2015
22 Jul · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Zydus Cadila setting up injectible facility in Gujarat". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
May 2015
21 May · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Cadila Eyes Claris Arm for Rs. 3,400 Cr". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
31 Dec · Legal
Exchange had sought clarification from Cadila Healthcare Limited with respect to a news item captioned "Wockhardt, Cadila & Hospira Voluntarily Recall Drugs in US". The Company has clarified that "The recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact".31 Dec · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Wockhardt, Cadila & Hospira Voluntarily Recall Drugs in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.17 Dec · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Cadila's US arm recalls 63,648 bottles of benzonatate capsules". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
21 Oct · Legal
Exchange had sought clarification from Cadila Healthcare Limited with respect to a news item captioned "Cadila Healthcare recalls hypertension drug in US". The Company has clarified that The news are correct, but Cadila Healthcare Limited does not envisage any impact of the same . .20 Oct · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Cadila Healthcare recalls hypertension drug in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.10 Oct · Legal
Exchange had sought clarification from Cadila Healthcare Limited has informed with respect to a news item captioned "Sun, Dr Reddy's, cadila named in US Congress price probe". The Company has clarified that "We confirm that our US subsidiary company has received recently a data request from US Congress relating to the price increase of 2 products being distributed by Zydus subsidiary in the US market. The article has no material impact on the Company".